Back to Search
Start Over
Use of a prognostic risk score that aggregates the FDG-PET/CT SUVmax, tumor size, and histologic group for predicting the prognosis of pStage I lung adenocarcinoma
- Source :
- International Journal of Clinical Oncology. 25:1079-1089
- Publication Year :
- 2020
- Publisher :
- Springer Science and Business Media LLC, 2020.
-
Abstract
- pStage I includes clinicopathologically diverse groups. This study aimed to identify the prognostic factors for pStage I lung adenocarcinoma.We retrospectively reviewed 208 patients with pStage I adenocarcinomas who underwent curative resection in our institute between 2006 and 2013. The maximum standardized uptake value (SUVmax) on [F18]-fluoro-deoxy-D-glucose positron emission tomography-computed tomography (PET/CT) was evaluated. Adenocarcinomas were categorized into the following histologic groups: group 0 (minimally invasive adenocarcinoma and lepidic predominant adenocarcinoma), group 1 (papillary predominant adenocarcinoma), and group 2 (acinar predominant adenocarcinoma and all the remaining subtypes). We assessed the relationship between disease-free survival (DFS) and clinicopathological factors.Multivariate analysis of DFS demonstrated that SUVmax 3.0 (p 0.001), total tumor size 20 mm (p = 0.016), and histologic groups (p 0.05) were independent prognostic factors. The prognostic risk score (PRS) was calculated using the following equation: PRS = SUVmax (≤ 3.0: 0 point, 3.0: 2 points) + total tumor size (≤ 20 mm: 0 point, 20 mm: 1 point) + histologic group (group 0: 0 point, group 1: 1 point, group 2: 2 points). Patients were divided into the following three risk groups: low-risk (PRS 0-2 points, n = 136), intermediate-risk (PRS 3-4 points, n = 49), and high-risk groups (PRS 5 points, n = 13). The 5-year DFS rates were 93.2%, 50.6%, and 30.8% for the low-, intermediate-, and high-risk groups, respectively (p 0.001).The PRS aggregating the FDG-PET/CT SUVmax, total tumor size, and histologic group predicts the prognosis of pStage I lung adenocarcinoma.
- Subjects :
- Male
0301 basic medicine
medicine.medical_specialty
Lung Neoplasms
Adenocarcinoma of Lung
Standardized uptake value
Gastroenterology
Disease-Free Survival
03 medical and health sciences
0302 clinical medicine
Fluorodeoxyglucose F18
Risk Factors
Surgical oncology
Positron Emission Tomography Computed Tomography
Internal medicine
medicine
Humans
Lung cancer
Aged
Retrospective Studies
Lung
Framingham Risk Score
medicine.diagnostic_test
business.industry
Histology
Hematology
General Medicine
Middle Aged
Prognosis
medicine.disease
Tumor Burden
030104 developmental biology
medicine.anatomical_structure
Oncology
Positron emission tomography
030220 oncology & carcinogenesis
Adenocarcinoma
Female
Surgery
Radiopharmaceuticals
business
Subjects
Details
- ISSN :
- 14377772 and 13419625
- Volume :
- 25
- Database :
- OpenAIRE
- Journal :
- International Journal of Clinical Oncology
- Accession number :
- edsair.doi.dedup.....696da991e1102714e3345f487a16c562